Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders Lab is deciphering the role of aggregation and ...

Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders Lab showed that small aggregates of alpha-synuclein ...

Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders Lab investigates the link between alpha-synuclein, disease and major cellular degradation pathways.

Tools created in Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders aid rapid screening of compound libraries for chemicals targeting oligomeric stage of fibrillization.

Mayo Clinic's Molecular Neurotherapeutics Lab cloned a neuron-specific tau kinase from the human brain tissue cDNA library ...

Mayo Clinic's Molecular Neurotherapeutics Lab demonstrated that maternal immune insults perturb microglial phenotypes and ...

Mayo Clinic's Molecular Neurotherapeutics Lab, led by Tsuneya Ikezu, M.D., Ph.D., has made significant contributions to the classification of the activation phenotype of microglia.

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...